Palladium Nanoplate-Based IL-6 Receptor Antagonists Ameliorate Cancer-Related Anemia and Simultaneously Inhibit Cancer Progression

Nano Letters ◽  
2022 ◽  
Author(s):  
Jianqiang Zhu ◽  
Qingfeng Fu ◽  
Shunhao Wang ◽  
Liting Ren ◽  
Wenya Feng ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Receptor Antagonists ◽  
Cancer Related Anemia

A combined treatment approach for cachexia and cancer-related anemia in advanced cancer patients: A randomized placebo-controlled trial.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 189-189 ◽  
Author(s):  
Clelia Madeddu ◽  
Giulia Gramignano ◽  
Luciana Tanca ◽  
Maria Cristina Cherchi ◽  
Carlo Aurelio Floris ◽  
...  
Keyword(s):  
Energy Metabolism ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Cancer Progression ◽  
Iron Metabolism ◽  
Combined Treatment ◽  
Advanced Cancer Patients ◽  
Tnf Α ◽  
Cancer Related Anemia ◽  
The Impact

189 Background: Cancer progression is characterized by specific energy metabolism alterations and by symptoms including fatigue, anorexia, nausea, depression, which results in cachexia syndrome and compromised quality of life (QL). This condition is often associated to anemia (cancer-related anemia, CRA), which negatively impacts patient QL and disease outcome. Methods: Adult advanced cancer patients with cachexia (i.e., weight loss > 5% in the previous 6 months) and CRA were randomly assigned (1:1 by computer generated list) to receive 3 months of a combined approach consisting of celecoxib (200 mg/day), L-carnitine (2 g/day), curcumin (Meriva) (4 g/day) and lactoferrin (200 mg/day) or placebo. The rationale for selecting these agents was: L-carnitine for modulating cell energy metabolism; celecoxib for counteracting inflammation, which is a key feature of cachexia; curcumin for its antiinflammatory and antioxidant action, without disregarding its action on the NF-kB and JAK-STAT pathway and the related synthesis of proinflammatory cytokines; lactoferrin for its ability to regulate iron metabolism in anemic cancer patients. Primary endpoints were improvement of lean body mass (LBM), appetite, fatigue and anemia. Additionally, we assessed the impact of treatment on the main metabolic/inflammatory and iron metabolism parameters: C-reactive protein (CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-α, leptin, reactive oxygen species (ROS), glutathione peroxidase, serum iron, ferritin, hepcidin and erythropoietin (EPO). Results: From January 2013 to March 2014, 66 patients have been enrolled. The combination arm was more effective than placebo arm in improving body weight, LBM, appetite, fatigue, and anemia. Among secondary parameters IL-6, TNF-α, CRP, ROS, ferritin, hepcidin and EPO decreased, while leptin increased significantly in the combination arm. No significant changes were observed in the placebo arm. Conclusions: To date a standard effective treatment of cancer cachexia is lacking. Our combined multitargeted approach was able to improve the nutritional and immunometabolic alterations of cachexia, ameliorate patient QL and correct CRA.

Abstract 3540: Targeting obesity-related cancer progression with novel leptin receptor antagonists

2017 ◽  
Author(s):  
Crystal C. Lipsey ◽  
Adriana Harbuzariu ◽  
Ruben R. Gonzalez-Perez
Keyword(s):  
Cancer Progression ◽  
Leptin Receptor ◽  
Receptor Antagonists

Activin receptor antagonists for cancer-related anemia and bone disease

2012 ◽  
Vol 22 (1) ◽  
pp. 87-101 ◽  
Author(s):  
Scott Z Fields ◽  
Shiroo Parshad ◽  
Madhurima Anne ◽  
Haralambos Raftopoulos ◽  
Mark J Alexander ◽  
...  
Keyword(s):  
Bone Disease ◽  
Receptor Antagonists ◽  
Activin Receptor ◽  
Cancer Related Anemia

scholarly journals Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1629
Author(s):  
Yu-Hsuan Lin ◽  
Yueh-Chien Lin ◽  
Chien-Chin Chen
Keyword(s):  
Cancer Progression ◽  
Lysophosphatidic Acid ◽  
Lipid Mediator ◽  
Membrane Phospholipids ◽  
Receptor Antagonists ◽  
Preclinical Trial ◽  
Lpa Receptor ◽  
Cellular Effects ◽  
Lpa Receptors ◽  
And Function

Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine production, thrombosis, fibrosis, angiogenesis, and lymphangiogenesis. Since the expression and function of LPA receptors are critical for cellular effects, selective antagonists may represent a potential treatment for a broad range of illnesses, such as cardiovascular diseases, idiopathic pulmonary fibrosis, voiding dysfunctions, and various types of cancers. More new LPA receptor antagonists have shown their therapeutic potentials, although most are still in the preclinical trial stage. This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer progression and resistance. Targeting LPA receptors can have potential applications in clinical patients with various diseases, including cancer.

Comparison of the central nervous system effects produced by six H1-receptor antagonists

1996 ◽  
Vol 26 (9) ◽  
pp. 1092-1097 ◽  
Author(s):  
F. E. R. SIMONS ◽  
T. G. FRASER ◽  
J. D. REGGIN ◽  
K. J. SIMONS
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
H1 Receptor ◽  
Receptor Antagonists ◽  
The Central Nervous System

463: Telomerase Inhibition Prevents Androgen Independent Osseous Prostate Cancer Progression

2005 ◽  
Vol 173 (4S) ◽  
pp. 126-127
Author(s):  
Yingming Li ◽  
Melissa Thompson ◽  
Zhu Chen ◽  
Bahaa S. Malaeb ◽  
David Corey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Cancer Progression ◽  
Telomerase Inhibition ◽  
Androgen Independent

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Progression ◽  
Specific Membrane ◽  
Psma Expression

951: TOB1 and ID-1 Two Novel Genes Implicated in Bladder Cancer Progression and Prognosis

2004 ◽  
Vol 171 (4S) ◽  
pp. 252-252
Author(s):  
Paul Perrotte ◽  
Nadia Benachenou ◽  
Pierre I. Karakiewicz ◽  
Myriam Senay ◽  
Fred Saad
Keyword(s):  
Bladder Cancer ◽  
Cancer Progression ◽  
Novel Genes
Sign in / Sign up

Export Citation Format

Share Document